

References

1. Arutyunov GP, Shavgulidze KB, Bylova NA. *Serdechnaya nedostatochnost – Heart Fail* 2008;9(3):128–36. (in Russ)
2. Bratus VV, Talaeva TV, Shumakov VA. – K.: Chetverta hvylya,2009.416 p. (in Russ)
3. Koval SN, Snegurskaya IA. *Zhural. NAMN Ukrayiny – J of the National Academy of Medical Sciences of Ukraine* 2011;17(2):174–85. (in Russ)
4. Mitchenko OI., KorpachevVV. *Metodychni rekomendatsii*. Kyiv,2009.42p. (in Ukr)
5. Mitchenko OI, Romanov VYu, Belyayeva TV Yakushko LV, Yanovska KO, Chulayevska IV. *Ukrainskyi kardiologichnyi Zhurnal – Ukr J Cardiol* 2009;1:48–53. (in Ukr)
6. *Rekomendatsii Asotsiatsii kardiologiv Ukrainy z diahnozyky, likuvannya ta profilaktyky hronichnoi sertsevoi nedostatnosti u doroslyh. – 2012.* (in Ukr)
7. Skybchyk VA. *Ukrainskyi medychnyi chasopys – Ukr Med J* 2006;6(56):61–8. (in Ukr)
8. Skybchyk VA, Skybchyk YV. *Ukrainskyi medychnyi chasopys – Ukr Med J* 2007;6(62)11–12:45–51. (in Ukr)
9. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. *Nature* 1996;382(6588):250–2.
10. Aizawa-Abe M. Pathophysiological role of leptin in obesity-related hypertension. *J Clin Invest* 2000;105:1243–52.
11. Azizi Ghanbari A, Drr R, Spitzer S, Stumpf J, Britz A, Amann-Zalan I, Ludwig V, Ulm B, Schnell O, Lohmann T. Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance. *Diab Vasc Dis Res* 2013;10(5):452–8.
12. Celik T, Yaman H. Elevated adiponectin levels in patients with chronic heart failure: an independent predictor of mortality or a marker of cardiac cachexia? *Int J Cardiol* 2010;144(2):319–20.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31–41.
14. Despres Jean-Pierre, Lemieux Isabelle, Bergeron Jean, Pibarot Philippe, Mathieu Patrick, Larose Eric, Rode?s-Cabau Josep, Bertrand F. Olivier, Poirier Paul. Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk. *Arteriosclerosis, Thrombosis, and Vascular* 2008;28:1039–49.
15. Dorner TE, Rieder A. Obesity paradox in elderly patients with cardiovascular diseases. *Int J Cardiol* 2012;155(1):56–65.
16. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. *Arterioscler Thromb Vasc Biol* 2007; 27:996–1003.
17. Fernandez-Riejos P, Najib S, Santos-Alvarez J, Mart'n-Romero C, P'rez-P'rez A, Gonzlez-Yanes C, S'nchez-Margalet V. Role of leptin in the activation of immune cells. *Mediators Inflamm* 2010;2010:568343.

18. Gil-Campos M, Canete R, Gil A. Hormones regulating lipid metabolism and plasma lipids in childhood obesity. *Inter J Obesity* 2004;28:S75–S80.
19. Kadoya M, Nakamura S, Sugio Y, Hiraoka H, Kurita M, Harada A, Matsumoto M, Nakanishi R, Sugiura T. Increased Body Mass Index in Young Adults is Associated with Metabolic Syndrome. *Sangyo Eiseigaku Zasshi* 2014 Jul 7. [Epub ahead of print] (in Jpn)
20. Kahn B. Barbara, Flier S. Jeffrey. Obesity and insulin resistance. *J Clin Invest* 2000;106(4):473–81.
21. Leibowitz SF. Specificity of hypothalamic peptides in the control of behavioral and physiological processes. *Ann NY Acad Sci* 1994;739:12–35.
22. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, AJS. Coats. Uric acid in chronic heart failure: a marker of chronic inflammation. *Eur Heart J* 1998;19(12):1814–22.
23. Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, CoatsAJ. Hyperleptinaemia in chronic heart failure. Relationship with insulin. *Eur Heart J* 1998;19(10):1547–51.
24. Lieb Wolfgang, Sullivan M. Lisa, Harris B. Tamara, Roubenoff Ronenn, Benjamin J. Emelia, Levy Daniel, Fox S. Caroline, Wang J. Thomas, Wilson W. Peter, Kannel B. William, Vasan S. Ramachandran. Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals. *Diabetes Care* 2009; 32(4): 612–6.
25. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2004;24(1):29–33.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model ment (HOMA): insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetol* 1985;28(7):412–9.
27. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, McMurray JJ. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. *Eur Heart J* 2007(Apr);28(7):829–35.
28. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in cachectic? patients with severe chronic heart failure. *Br Heart J.* 1991;66(5):356–8.
29. Minocci A, Savia G, Lucantoni R, Berselli ME, Tagliaferri M, Cal G, Petroni ML, de Medici C, Viberti GC, Liuzzi A. Leptin plasma concentrations are dependent on body fat distribution in obese patients. *Intern J Obes* 2000;24,1139–44.
30. Mitrou Panayota, Raptis A. Sotirios, Dimitriadis George. Insulin action in morbid obesity: a focus on muscle and adipose tissue. *Hormones* 2013, 12(2):201–13.
31. Otero M, Lago R, Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Leptin: a metabolic hormone that functions like a proinflammatory adipokine. *Drug News Perspect* 2006;19(1):21–6.
32. Palou A, Serra F, Bonet ML, Pico C. Obesity: molecular bases of a multifactorial problem. *Eur J Nutr* 2000;39,127–44.

33. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. *Mol Med*. 2008;14(11-12):741-51.
34. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, Lauretani F, Bandinelli S, Senin U, Ferrucci L Uric acid and inflammatory markers. *Eur Heart J* 2006;27:1174-81.
35. Sacca Luigi. Heart Failure as a Multiple Hormonal Deficiency Syndrome. *Circ Heart Fail* 2009;2:151-6.
36. Schulze P, Christian, Biolo Andreaia, Gopal Deepa, Shahzad Khurram, Balog Joshua, Fish Mark, Siwik Deborah, Colucci S. Wilson. Dynamics in Insulin Resistance and Plasma Levels of Adipokines in Patients with Acute Decompensated and Chronic Stable Heart Failure. *J Card Fail Dec* 2011;17(12):1004-11.
37. Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S, Erbs S, Moebius-Winkler S, Schuler G. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. *Eur J Heart Fail* 2003;5(1):33-40.
38. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. *Endocr Regul* 2009;43(4):157-68.
39. Tchernof A, Lamarche B, Prud'homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. *Diabetes Care* 1996;19:629-37.
40. Uriel N, Gonzalez-Costello J, Mignatti A, Morrison KA, Nahumi N, Colombo PC, Jorde UP. Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. *JACC Heart Fail* 2013;1(4):331-7.
41. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). *Circulation* 2001;104(25):3052-6.
42. Wisniacki N, Taylor W, Lye M, Wilding JP. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. *Heart* 2005;91(1):32-7.
43. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. *J Am Coll Cardiol* 2008;51(2):93-102.